Arzerra (ofatumumab) Information

Arzerra (ofatumumab) is in a class of drugs called anti-CD20-directed monoclonal antibodies. It is used to treat chronic lymphocytic leukemia (CLL) in patients who have further disease after treatment with the anti-cancer drugs fludarabine and alemtuzumab.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.


Regulatory History and Labeling from Drugs@FDA

Contact FDA

1-800-FDA-0178 Fax
Report a Serious Problem

MedWatch Online

Regular Mail: Use postage-paid FDA Form 3500

Mail to: MedWatch 5600 Fishers Lane

Rockville, MD 20857

Page Last Updated: 07/09/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.